Please login to the form below

Not currently logged in

elivaldogene autotemcel

This page shows the latest elivaldogene autotemcel news and features for those working in and with pharma, biotech and healthcare.

bluebird bio sells second FDA priority review voucher for $95m

bluebird bio sells second FDA priority review voucher for $95m

bluebird bio received two PRVs upon the FDA approvals of Zynteglo (betibeglogene autotemcel) for the treatment of beta-thalassaemia in adult and paediatric patients requiring regular red blood cell transfusions, and ... Skysona (elivaldogene autotemcel)

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Subscribe to our email news alerts


Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...